BGB-283 is a dual RAF/EGFR inhibitor. It inhibits BRAF(V600E)-activated ERK phosphorylation and cell proliferation in vitro. This activity slows cell proliferation and tumor growth in BRAF(V600E) colorectal cancer cell lines, something that BRAF inhibitors vemurafenib and dabrafenib have been unable to achieve.
Uniformity of Dosage Units
Allschoolabs
Uniformity of Dosage Units is a specialised analytical laboratory service that assesses whether individual dosage units contain sufficiently consis...



































